Boston, MA – June 26, 2024 – Moderna, a pioneer in messenger RNA (mRNA) therapeutics, today unveiled an expansive vision for its groundbreaking platform at its annual Science Day, detailing a multi-horizon strategy aimed at revolutionizing treatments for a broad spectrum of diseases. The company showcased a robust pipeline, emphasizing its commitment to advancing infectious disease vaccines, cancer vaccines, and rare disease therapeutics, with a particular spotlight on a preclinical in vivo candidate poised to enter clinical trials.
The biotech giant’s forward-looking presentation underscored a strategic balance between near-term commercial growth and the relentless pursuit of next-generation mRNA medicines. Moderna’s existing portfolio, which includes four approved products – Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX – serves as the foundation for this ambitious expansion. The company is actively driving growth through new infectious disease launches, expanding its global reach, and accelerating the development of late-stage pipeline opportunities. These include the investigational intisomeran autogene therapy and a promising therapeutic for propionic acidemia.
Simultaneously, Moderna’s Research and Early Development (mRED) division is diligently focused on pioneering emerging and future modalities, propelling high-potential programs towards crucial clinical proof-of-concept and first-in-human (FIH) milestones. This dual approach, characterized by Stéphane Bancel, CEO of Moderna, as "working across three strategic horizons," encapsulates the company’s commitment to both scaling and validating its existing mRNA expertise while simultaneously exploring uncharted therapeutic territories.
The Three Horizons: A Strategic Framework for Innovation
Moderna has meticulously structured its development pipeline into three distinct "Horizon" programs, each representing a different stage of therapeutic advancement and strategic focus. This framework allows for a clear categorization of its mRNA therapies, ensuring a systematic progression from discovery to commercialization.
Horizon 1: Established Modalities and Commercial Success
Horizon 1 encompasses Moderna’s late-stage and already approved products. This segment is crucial for driving immediate commercial success and providing the financial impetus for further research and development. The company is committed to not only maintaining the momentum of these established modalities but also to continuously fostering innovation within them. This includes optimizing manufacturing processes, exploring new indications, and ensuring a seamless, end-to-end path from initial discovery through to robust commercialization. The continued success in Horizon 1 underpins Moderna’s ability to invest heavily in the more speculative, yet potentially transformative, Horizon 2 and Horizon 3 programs.
Horizon 2: Emerging Modalities in the Clinic
Horizon 2 is dedicated to emerging mRNA modalities that have already entered clinical trials. These programs are actively being scaled and expanded by mRED, with the overarching goal of achieving clinical proof-of-concept in human subjects. The majority of these candidates are currently undergoing Phase I/II trials, with a significant concentration in the field of oncology. However, Horizon 2 also features a promising multiple sclerosis (MS) therapeutic that has advanced to Phase II trials, demonstrating the platform’s versatility across different therapeutic areas.
Key candidates within the Horizon 2 program include:
- mRNA-4106: Currently in a Phase I study targeting solid tumors, this candidate represents Moderna’s ongoing efforts to leverage mRNA technology for cancer treatment.
- mRNA-4200: Set to advance into a Phase I study in combination with Keytruda (pembrolizumab), an established immunotherapy, this program aims to enhance the efficacy of existing cancer treatments in advanced solid tumors. The synergistic approach highlights Moderna’s strategy of combining novel mRNA therapies with established drug regimens.
- mRNA-4194: This candidate is progressing through the second portion of an ongoing Phase I/II trial. Its evaluation is focused on first-line metastatic melanoma and first-line metastatic non-small cell lung cancer (NSCLC), two aggressive forms of cancer where innovative treatment options are desperately needed.
In addition to these, three other significant candidates are part of the Horizon 2 program, each in varying stages of development:
- mRNA-2808: Targeted at multiple myeloma, a blood cancer, this program represents another facet of Moderna’s oncology pipeline.
- mRNA-2151: This candidate is being investigated for its potential in treating ovarian cancer, a disease with historically challenging treatment outcomes.
- mRNA-1195: This program is focused on developing an mRNA therapeutic for multiple sclerosis, a chronic autoimmune disease affecting the central nervous system.
The progression of these diverse candidates through clinical trials underscores Moderna’s deep commitment to validating the efficacy and safety of its mRNA platform across a wide array of challenging diseases.
Horizon 3: Future Modalities on the Cusp of Clinical Development
Horizon 3 represents Moderna’s most forward-looking endeavors, focusing on future modalities with the potential to reach first-in-human (FIH) clinical trials by the end of 2027. This horizon is where truly novel applications of mRNA technology are being explored, pushing the boundaries of what is currently possible in medicine.
The flagship candidate within the Horizon 3 program is mRNA-6007. This revolutionary asset is an in vivo CAR-T therapy, a groundbreaking approach designed to enable deep B-cell depletion for autoimmune conditions. The therapy utilizes a multiplexed mRNA strategy delivered via targeted lipid nanoparticles (LNPs). The core innovation lies in its ability to deliver mRNA directly into immune cells in vivo, thereby facilitating transient CAR expression and potentially inducing a profound immune reset. The initial clinical focus for mRNA-6007 is systemic lupus erythematosus (SLE), a chronic autoimmune disease, and other B-cell-mediated autoimmune diseases. This represents a significant paradigm shift, moving from ex vivo cell modification to direct in vivo genetic reprogramming of immune cells.
The Promise of In Vivo Therapies and Advanced Technologies
Moderna’s CEO, Stéphane Bancel, articulated the company’s strategic vision with clarity: "Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T." This statement highlights the company’s relentless drive to innovate and bring novel therapeutic approaches to patients.
The emphasis on in vivo therapies, particularly mRNA-6007, signifies a major leap forward. Traditional CAR-T therapies, while effective, require the complex and time-consuming process of extracting a patient’s T-cells, genetically modifying them in a lab, and then reinfusing them. An in vivo approach promises to streamline this process, potentially making these life-changing therapies more accessible and efficient. The ability to deliver genetic instructions directly into the body to engineer immune cells opens up unprecedented possibilities for treating a range of conditions, from autoimmune diseases to certain cancers.
Furthermore, Bancel highlighted Moderna’s strategic investment in cutting-edge technologies: "At the same time, we are driving innovation by using data, AI and machine learning, and robotics to accelerate discovery and continuously improve how we execute for near-term growth while fuelling the next generation of mRNA medicines for patients around the world." This integration of artificial intelligence, machine learning, and robotics is critical for optimizing every stage of the drug development lifecycle, from identifying novel drug targets and designing therapeutic molecules to streamlining clinical trial operations and manufacturing. By leveraging these advanced tools, Moderna aims to significantly shorten development timelines, reduce costs, and enhance the precision and efficacy of its mRNA-based medicines.
Navigating the Regulatory Landscape: A Mixed Recent History
Moderna’s Science Day discussions also occur against a backdrop of recent regulatory developments, underscoring the dynamic and often challenging nature of bringing novel therapeutics to market. The company recently achieved a significant milestone with its mRNA influenza vaccine, mRNA-1010, receiving a recommendation for approval from a U.S. Food and Drug Administration (FDA) Advisory Committee (AdCom). This positive vote represents a crucial turnaround for Moderna’s prospects in the U.S. vaccine sector, especially considering the earlier regulatory hurdles encountered with this specific candidate.
Earlier in the year, the FDA had declined to accept Moderna’s application for review of mRNA-1010, citing a lack of a properly conducted study. This decision highlighted the stringent requirements for clinical trial design and execution, even for established vaccine platforms. The subsequent positive AdCom recommendation suggests that Moderna has successfully addressed the FDA’s concerns and provided compelling data to support the vaccine’s efficacy and safety.
In a broader context, the landscape for mRNA research funding has seen shifts. In August, the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) experienced a significant reduction in funding, with RFK Jr. reportedly cutting $500 million worth of mRNA vaccine research funding. This substantial cut impacted approximately 22 projects being run under BARDA’s purview. Experts interviewed by Pharmaceutical Technology, a sister publication of Clinical Trials Arena, indicated that these funding challenges have also cast a shadow over the mRNA cancer vaccine space, presenting new hurdles for pioneers in this field. While this funding cut may not directly impede Moderna’s proprietary development programs, it signals a potential tightening of the broader research ecosystem for mRNA technologies, emphasizing the importance of robust internal funding and strategic partnerships.
Supporting the mRNA Ecosystem: The Role of Key Partners
The advancement of mRNA therapeutics is a complex undertaking that relies on a robust ecosystem of specialized partners. As highlighted in the article, coverage of mRNA vaccine developments on platforms like Pharmaceutical Technology and Clinical Trials Arena is supported by companies like Trilink Biotechnologies. Trilink plays a critical role in the mRNA supply chain by providing high-quality nucleoside triphosphates (NTPs) and other critical reagents essential for the synthesis of mRNA. Their contributions are vital for ensuring the integrity and scalability of mRNA production, a foundational element for both research and commercial manufacturing.
Moderna’s strategic vision, coupled with the ongoing advancements in mRNA technology and the support of key industry partners, positions the company at the forefront of a new era in medicine. The company’s commitment to a multi-horizon approach, its investment in cutting-edge technologies, and its focus on novel delivery methods like in vivo CAR-T therapies suggest a future where mRNA technology will continue to unlock transformative treatments for a wide range of unmet medical needs. The journey from preclinical research to approved therapies is long and arduous, but Moderna’s Science Day presentation paints a compelling picture of a company resolutely charting a course towards a healthier future for patients worldwide.
About the Author
